CooperVision announces new seven-year findings from its pivotal MiSight® 1 day contact lens clinical trial. Twelve months following treatment cessation, mean axial elongation data indicate no evidence of rebound effect, meaning the myopia control gains are retained. The study is the world’s longest continuous running soft contact lens clinical trial for myopia control. CooperVision previously reported that MiSight® 1 day showed sustained slowing of myopia progression across multiple years of treatment. This was observed in a cohort that wore MiSight® 1 day for the study’s first six years as well as the original control group who were switched into MiSight® 1 day for three years. “Our unparalleled research clearly illustrates the tremendous potential of MiSight® 1 day for children of different ages and with different levels of myopia, regardless of when they start treatment. With these results, eye care professionals should be even more confident in prescribing MiSight® 1 day,” said Paul Chamberlain, BSc (Hons), MCOptom, the study’s principal investigator and CooperVision Director of Research Programs. MiSight® 1 day contact lenses are specifically designed for myopia control and are FDA* approved to slow the progression of myopia in children aged 8-12 at the initiation of treatment. In August, MiSight® 1 day received approval from the Chinese National Medical Products Administration (NMPA) to become the first indicated product of any type that may slow the progression of axial length. MiSight® 1 day contact lenses are already being successfully worn by thousands of myopic children in the UK and across the world.